Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label, Multiple-Dose Study to Evaluate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-6058 in Subjects With Sickle Cell Disease (SCD)

NCT05169580 is registered in ClinicalTrials.gov with Fulcrum Therapeutics as lead sponsor.

NCT NCT05169580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05169580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label, Multiple-Dose Study to Evaluate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-6058 in Subjects With Sickle Cell Disease (SCD)
Lead sponsor
Fulcrum Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
December 13, 2021
Completion date
January 20, 2026
Enrollment
45 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell anemia, sickle cell disease